---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-042502"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:34:42.642156+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics CFO Peter Pfreundschuh to resign; Robin Swartz appointed as principal financial officer

## Summary
- CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.
- Robin Swartz, current COO, appointed principal financial and accounting officer effective April 12.
- Pfreundschuh receives salary continuation for 12 months, prorated 2024 bonus, and health insurance.
- Unvested equity awards continue to vest during consulting period up to ~July 2024.
- Separation Agreement includes release of claims and non-disparagement obligations.

## SEC filing metadata
- accession: 0001104659-24-042502
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924042502/0001104659-24-042502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924042502/tm2410417d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-042502
- JSON: https://secwatch.observer/filing/0001104659-24-042502.json
- Plain text: https://secwatch.observer/filing/0001104659-24-042502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.